{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:07:49Z","timestamp":1790327269313,"version":"4.1.0"},"reference-count":33,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer United States","award":["na"],"award-info":[{"award-number":["na"]}]},{"name":"Pfizer United States","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>COX-2 selective inhibitors (COXIBs) are non-steroidal anti-inflammatory drugs (NSAIDs), with fewer side effects compared with non-selective NSAIDs, and are used for the treatment of arthritis, headaches, and other inflammatory diseases of the brain and peripheral tissues. Radiolabeled COXIBs may permit positron emission tomography (PET) imaging of COX-2 localization and activity in diseases, enable monitoring of inflammatory processes, and determine target occupancy of COX-2 activity by NSAIDs, thus, accelerating the development of novel CIXIBs. We synthesized [11C]celecoxib, one of the COXIBs and a prescription drug, and here report its in vivo uptake in the brain, whole body biodistribution, and radiation dosimetry in baboons using PET. Brain imaging experiments were performed in one baboon and whole body PET scans were performed in triplicates in two male baboons using an ECAT ACCEL (Siemens Medical Solutions, Inc. Knoxville) under anesthetic conditions. PET studies in baboons show that [11C]celecoxib penetrates the blood brain barrier (BBB) and accumulates in the brain, followed by a washout of radioactivity. The liver has the highest residence time and the gallbladder is the critical organ for [11C]celecoxib. Organ Level Internal Dose Assessment (OLINDA) estimates indicate that the maximum permissible single study dosage of [11C]celecoxib in humans is 1110 MBq (30 mCi) for both males and females under the 21 CFR 361.1 dose limit for research subjects.<\/jats:p>","DOI":"10.3390\/molecules23081929","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T03:03:15Z","timestamp":1533265395000},"page":"1929","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["In Vivo Brain Imaging, Biodistribution, and Radiation Dosimetry Estimation of [11C]Celecoxib, a COX-2 PET Ligand, in Nonhuman Primates"],"prefix":"10.3390","volume":"23","author":[{"given":"J. S. Dileep","family":"Kumar","sequence":"first","affiliation":[{"name":"Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Bai","sequence":"additional","affiliation":[{"name":"Now at Department of Radiology, University of Southern California, Los Angeles, CA 90089, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-0676","authenticated-orcid":false,"given":"Francesca","family":"Zanderigo","sequence":"additional","affiliation":[{"name":"Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA"},{"name":"Department of Psychiatry, Columbia University, New York 10032, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"DeLorenzo","sequence":"additional","affiliation":[{"name":"Now at Department of Psychiatry, Stony Brook School of Medicine, Stony Brook, New York, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Prabhakaran","sequence":"additional","affiliation":[{"name":"Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA"},{"name":"Department of Psychiatry, Columbia University, New York 10032, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin V.","family":"Parsey","sequence":"additional","affiliation":[{"name":"Now at Department of Psychiatry, Stony Brook School of Medicine, Stony Brook, New York, NY 11794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. John","family":"Mann","sequence":"additional","affiliation":[{"name":"Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA"},{"name":"Department of Psychiatry, Columbia University, New York 10032, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2174\/1381612043453144","article-title":"Cyclooxygenase enzymes: Regulation and function","volume":"6","author":"Fitzpatrick","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1021\/jm0613166","article-title":"Structural and functional basis of cyclooxygenase inhibition","volume":"50","author":"Blobaum","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1194\/jlr.R800042-JLR200","article-title":"Cyclooxygenases: Structural and functional insights","volume":"50","author":"Rouzer","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.56.3.3","article-title":"Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition","volume":"56","author":"Simmons","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"13926","DOI":"10.1073\/pnas.162468699","article-title":"COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic\/antipyretic drugs: Cloning, structure, and expression","volume":"99","author":"Chandrasekharan","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0006-8993(99)01389-X","article-title":"Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs","volume":"830","author":"Yasojima","year":"1999","journal-title":"Brain Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1097-4547(19990801)57:3<295::AID-JNR1>3.0.CO;2-0","article-title":"Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer\u2019s disease","volume":"57","author":"Ho","year":"1999","journal-title":"J. Neurosci. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1111\/j.1582-4934.2008.00430.x","article-title":"Cyclooxygenase in normal human tissues\u2014Is COX-1 really a constitutive isoform, and COX-2 an inducible isoform?","volume":"13","author":"Zidar","year":"2009","journal-title":"J. Cell Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/13543784.2016.1161756","article-title":"Celecoxib for the treatment of atherosclerosis","volume":"25","author":"Papageorgiou","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejphar.2015.11.007","article-title":"Cyclooxygenase-2 inhibitors in lung cancer treatment: Bench to bed","volume":"769","author":"Liu","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_11","first-page":"1","article-title":"Protective role of NSAIDs in the treatment of nonmelanoma skin cancer: A comprehensive review on animal and human trial studies","volume":"2","author":"Venkat","year":"2013","journal-title":"J. Pharma. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40266-015-0239-z","article-title":"Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer\u2019s disease: A systematic review and meta-Analysis of treatment effect","volume":"32","author":"Marina","year":"2015","journal-title":"Drugs Aging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.2174\/1568026617666170821124947","article-title":"Update on COX-2 selective inhibitors: Chemical classification, side effects and their use in cancers and neuronal diseases","volume":"17","author":"Rayar","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm960803q","article-title":"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib)","volume":"40","author":"Penning","year":"1997","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1073\/pnas.95.22.13313","article-title":"Pharmacological analysis of cyclooxygenase-1 in inflammation","volume":"95","author":"Smith","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","first-page":"1","article-title":"Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: A systematic review","volume":"46","author":"Mateos","year":"2010","journal-title":"Drugs Today (Barc.)"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.bmc.2006.11.033","article-title":"Synthesis and in vivo evaluation of [18F]celecoxib: A potential PET probe for imaging COX-2 expression","volume":"15","author":"Prabhakaran","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0090-9556(24)15094-5","article-title":"Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats","volume":"28","author":"Paulson","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0090-9556(24)15366-4","article-title":"Metabolism and excretion of [14C]celecoxib in healthy male volunteers","volume":"28","author":"Paulson","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/jlcr.1002","article-title":"Synthesis of [11C]celebrex: A PET probe for COX-2 expression","volume":"48","author":"Prabhakaran","year":"2005","journal-title":"J. Label. Compd. Radiopham."},{"key":"ref_21","unstructured":"(2018, July 25). NIMH-PDSP. Available online: https:\/\/pdspdb.unc.edu\/pdspWeb\/."},{"key":"ref_22","unstructured":"Roth, B.L. (2018, July 25). NIMH-PDSP Assay Protocol Book. Available online: https:\/\/pdspdb.unc.edu\/pdspWeb\/content\/UNC-CH%20Protocol%20Book.pdf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","article-title":"Graphical analysis of reversible radioligandbinding from time-activity measurements applied to [N-11C-methyl-(2)-cocaine PET studies in human subjects","volume":"10","author":"Logan","year":"1990","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1002\/sim.1562","article-title":"Estimation of kinetic parameters in graphical analysis of PET imaging data","volume":"22","author":"Ogden","year":"2003","journal-title":"Stat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00004647-200106000-00002","article-title":"Positron emission tomography compartmental models","volume":"21","author":"Gunn","year":"2001","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/jm050725j","article-title":"Synthesis and in vivo validation of [11C]MPT: A potential 5-HT1A receptor agonist PET ligand","volume":"49","author":"Kumar","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1006\/nimg.1998.0379","article-title":"Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET","volume":"8","author":"Gunn","year":"1998","journal-title":"Neuroimage"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.nucmedbio.2004.09.002","article-title":"Biodistribution and radiation dosimetry of [11C]DASB in baboons","volume":"31","author":"Simpson","year":"2004","journal-title":"Nucl. Med. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00006231-200510000-00005","article-title":"Amyloid plaque imaging agent [C-11]-6-OH-BTA-1: Biodistribution and radiation dosimetry in baboon","volume":"26","author":"Parsey","year":"2005","journal-title":"Nucl. Med. Commun."},{"key":"ref_30","first-page":"614","article-title":"Biodistribution and Radiation Dosimetry of 11C-WAY100,635 in Humans","volume":"46","author":"Parsey","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/MNM.0b013e32827420b5","article-title":"Biodistribution and radiation dosimetry of 11C-harmine in baboons","volume":"28","author":"Murthy","year":"2007","journal-title":"Nucl. Med. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1177\/1091581811419024","article-title":"Biodistribution, toxicology, and radiation dosimetry of 5-HT1A-receptor agonist positron emission tomography ligand [11C]CUMI-101","volume":"30","author":"Kumar","year":"2011","journal-title":"Int. J. Toxicol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00259-006-0226-z","article-title":"Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND)","volume":"34","author":"Visser","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/8\/1929\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:16:07Z","timestamp":1760195767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/8\/1929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["molecules23081929"],"URL":"https:\/\/doi.org\/10.3390\/molecules23081929","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]}}}